Stock Research for NYMX


Featured Broker: Ally Invest

Get the due diligence for another stock.


NYMX Stock Chart & Research Data

The NYMX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the NYMX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


NYMX Due diligence Resources & Stock Charts

The NYMX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View NYMX Detailed Price Forecast - CNN Money CNN View NYMX Detailed Summary - Google Finance
Yahoo View NYMX Detailed Summary - Yahoo! Finance Zacks View NYMX Stock Research & Analysis -

Stock Analysis

TradeIdeas View NYMX Trends & Analysis - Trade-Ideas Barrons View NYMX Major Holders - Barrons
NASDAQ View NYMX Call Transcripts - NASDAQ Seeking View NYMX Breaking News & Analysis - Seeking Alpha
Spotlight View NYMX Annual Report - OTC Report View NYMX OTC Short Report -
TradeKing View NYMX Fundamentals - TradeKing Charts View NYMX SEC Filings - Bar Chart
WSJ View Historical Prices for NYMX - The WSJ Morningstar View Performance/Total Return for NYMX - Morningstar
MarketWatch View the Analyst Estimates for NYMX - MarketWatch CNBC View the Earnings History for NYMX - CNBC
StockMarketWatch View the NYMX Earnings - StockMarketWatch MacroAxis View NYMX Buy or Sell Recommendations - MacroAxis
Bullish View the NYMX Bullish Patterns - American Bulls Short Pains View NYMX Short Pain Metrics -

Social Media Mentions

StockTwits View NYMX Stock Mentions - StockTwits PennyStocks View NYMX Stock Mentions - PennyStockTweets
Twitter View NYMX Stock Mentions - Twitter Invest Hub View NYMX Investment Forum News - Investor Hub
Yahoo View NYMX Stock Mentions - Yahoo! Message Board Seeking Alpha View NYMX Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for NYMX - Insider Cow View Insider Transactions for NYMX - Insider Cow
CNBC View NYMX Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for NYMX - OTC Markets
Yahoo View Insider Transactions for NYMX - Yahoo! Finance NASDAQ View Institutional Holdings for NYMX - NASDAQ

Stock Charts

FinViz View NYMX Stock Insight & Charts - StockCharts View NYMX Investment Charts -
BarChart View NYMX Stock Overview & Charts - BarChart Trading View View NYMX User Generated Charts - Trading View

Latest Financial News for NYMX

Nymox: 3Q Earnings Snapshot
Posted on Tuesday November 13, 2018

The St. Laurent, Quebec-based company said it had a loss of 5 cents per share. The biopharmaceutical company posted revenue of $40,000 in the period. In the final minutes of trading on Tuesday, the company's ...

Corporate Update To Shareholders: Preparatory Work For Regulatory Filings On Track
Posted on Thursday October 11, 2018

Regulatory Filings for Fexapotide in BPH: The Company is pleased with the progress its regulatory filings for its lead product, Fexapotide Triflutate, are making for BPH (Benign Prostatic Hyperplasia) both in Europe and the United States. The successful financing earlier this summer has allowed the Company to expand its work with top-end regulatory teams on both continents. Quality Control: The Company has augmented its internal quality control activities with an expanded team and a new office located in Orange County, California.

Nymox Reports 78 Month Results From Biopsy and Surgery Confirmed Prospective Randomized NX03-0040 Prostate Cancer Study of Fexapotide Triflutate: Gleason Grade Progression Reduced by 81% Overall and Fexapotide 15mg Minimal Treatment Leads to 73% Long-Term Reduction in Incidence of Associated Prostate Cancer Surgery and Radiotherapy
Posted on Tuesday October 09, 2018

Nymox Pharmaceutical Corporation (NYMX) is pleased to announce today important new long-term clinical trial results from the Company's 146 patient Phase IIb NX03-0040 Fexapotide (FT) U.S. study for low grade localized prostate cancer. Paul Averback, CEO of Nymox, said, "These exciting new results confirm and expand the evidence for the beneficial long-term effect of a virtually painless and safe minimal administration of Fexapotide Triflutate to men with low grade localized prostate cancer.

Nymox Reports Safety Benefits of Fexapotide Treatments for Prostate Cancer and Benign Prostatic Hyperplasia
Posted on Wednesday October 03, 2018

HASBROUCK HEIGHTS, N.J., Oct. 03, 2018 -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) reported today that after long-term safety assessments of repeated Fexapotide.

Stock Market & Investing Books

Enter a stock symbol to view the stock details.